2i0e: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
[[Image:2i0e.gif|left|200px]]
{{Seed}}
[[Image:2i0e.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2i0e|  PDB=2i0e  |  SCENE=  }}  
{{STRUCTURE_2i0e|  PDB=2i0e  |  SCENE=  }}  


'''Structure of catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor'''
===Structure of catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor===




==Overview==
<!--
The conventional protein kinase C isoform, PKCII, is a signaling kinase activated during the hyperglycemic state and has been associated with the development of microvascular abnormalities associated with diabetes. PKCII, therefore, has been identified as a therapeutic target where inhibitors of its kinase activity are being pursued for treatment of microvascular-related diabetic complications. In this report, we describe the crystal structure of the catalytic domain of PKCbetaII complexed with an inhibitor at 2.6 A resolution. The kinase domain of PKCbetaII was cleaved and purified from full-length PKCbetaII expressed in baculovirus-infected insect cells. The overall kinase domain structure follows the classical bilobal fold and is in its fully activated conformation with three well-defined phosphorylated residues: Thr-500, Thr-641, and Ser-660. Different from the crystal structures of nonconventional PKC isoforms, the C-terminus of the PKCbetaII catalytic domain is almost fully ordered and features a novel alpha helix in the turn motif. An ATP-competitive inhibitor, 2-methyl-1H-indol-3-yl-BIM-1, was crystallized with the PKCbetaII catalytic domain as a dimer of two enzyme-inhibitor complexes. The bound inhibitor adopts a nonplanar conformation in the ATP-binding site, with the kinase domain taking on an intermediate, open conformation. This PKCbetaII-inhibitor complex represents the first structural description of any conventional PKC kinase domain. Given the pathogenic role of PKCbetaII in the development of diabetic complications, this structure can serve as a template for the rational design of inhibitors as potential therapeutic agents.
The line below this paragraph, {{ABSTRACT_PUBMED_17115692}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 17115692 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_17115692}}


==About this Structure==
==About this Structure==
Line 28: Line 32:
[[Category: Protein kinase c beta ii]]
[[Category: Protein kinase c beta ii]]
[[Category: Serine/threonine protein kinase]]
[[Category: Serine/threonine protein kinase]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May  4 06:55:41 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 06:17:37 2008''

Revision as of 06:17, 29 July 2008

File:2i0e.png

Template:STRUCTURE 2i0e

Structure of catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitorStructure of catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor

Template:ABSTRACT PUBMED 17115692

About this StructureAbout this Structure

2I0E is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

ReferenceReference

Structure of the catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor., Grodsky N, Li Y, Bouzida D, Love R, Jensen J, Nodes B, Nonomiya J, Grant S, Biochemistry. 2006 Nov 28;45(47):13970-81. PMID:17115692

Page seeded by OCA on Tue Jul 29 06:17:37 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA